30 Jun 2026

CRC Research Update — June 30, 2026

Creator: The CRC Digest
Published: 2026-06-30T21:54:21Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Improved Regorafenib Dosing for Refractory Metastatic Colorectal Cancer
New dosing strategies for regorafenib show promise in patients with refractory metastatic colorectal cancer who have exhausted standard treatment options. (NEJM Clinician)
Early ctDNA Changes Predict Fruquintinib Response Before Imaging
In a prospective study of refractory metastatic CRC patients, circulating tumor DNA levels measured at day 28 predicted treatment response and survival with fruquintinib before imaging could detect changes. (Front Med)
Alpelisib Plus Capecitabine Shows Activity in PIK3CA-Mutant Metastatic CRC
A phase II trial of 26 patients with PIK3CA-mutant metastatic CRC found median progression-free survival of 3.5 months and overall survival of 8.8 months, with better outcomes in patients without KRAS mutations or liver metastases. (Sci Rep)
MMR Protein Expression Patterns Vary by Patient Characteristics
A study of 80 Chinese CRC patients examined how deficient mismatch repair status relates to clinical features, providing insights into this key molecular subtype that affects immunotherapy response. (Front Med)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

African American Patients Share Barriers to CRC Screening at Community Health Centers
Focus groups and stakeholder interviews explored multilevel barriers to colorectal cancer screening among African American patients in north Florida community health centers. (BMC Public Health)
Swedish Fast-Track Pathway Shows Age-Related Differences in Colonoscopy Outcomes
A retrospective study of 3,258 patients in Sweden's symptom-based fast-track diagnostic pathway found varying colonoscopy outcomes and referral-factor associations across age groups. (Ther Adv Gastroenterol)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Lynch Syndrome Presents with Cholangiocarcinoma and Urothelial Cancer, No GI Tumor
A case report describes a man in his late 50s with Lynch syndrome confirmed by MSH2/MSH6 loss who developed cholangiocarcinoma and urothelial malignancy but no gastrointestinal tumor. (BMJ Case Rep)

Stay informed, stay hopeful — research continues to advance our understanding and treatment of colorectal cancer.

CRC Research Update

Subscribe to The CRC Digest